Targeted alpha therapy for selected advanced cancer cases.
Request Medical OpinionAdvanced treatment information for international patients and healthcare professionals.
Actinium-225 is a targeted alpha-emitting radionuclide therapy used in selected advanced oncology cases after specialist evaluation.
Selected prostate cancer cases and other receptor-positive advanced tumors may be evaluated depending on molecular imaging results.
Eligibility depends on diagnosis, PET uptake, previous therapies, organ function and clinical status.
Patients may need PSMA PET/CT or other receptor-based imaging before treatment planning.
The dose, number of cycles and treatment interval are planned individually.
Response monitoring may include laboratory tests, imaging and clinical evaluation.
Targeted delivery may help focus treatment effect on selected tumor cells.
Final suitability and cost are confirmed only after full medical file review.
Patients should submit medical reports, imaging files, pathology results, previous treatment history and current clinical information.
Our team organizes the case and coordinates specialist evaluation before treatment planning, estimated duration and quotation.
Submit Your ReportsTreatment suitability, protocol, number of sessions, hospital stay and cost depend on diagnosis, disease stage, previous treatments and specialist evaluation.
Send your reports and receive professional treatment planning support.